Asthma vaccine showed long-term efficiency in animals


One injection was protected by animals at least a year from heavy symptoms of an allergic reaction and did not cause side effects. People have scientists expect to use it for the prevention and treatment of the disease, including the most severe forms of the disease. Ahead clinical trials.

A team of researchers from France and developers from NEOVACS presented a new vaccine from asthma, which is able to provide long-term protection against exhausting symptoms of asthma, as well as reduce their severity in the most severe cases. Study

For allergic asthma, hypersensitivity to certain allergens is characteristic, most often to dust mites. The effect of dust ticks and other allergens leads to the development of immunoglobulin E (IgE) and inflammatory cytokines (IL-4 and IL-13) in the respiratory tract. These events provoke a whole cascade of reactions resulting in the hypersensitivity of the respiratory tract, excessive rehabilitation of mucus and eosonophilia.

A year after the injection of 60% of rodents retained the level of antibodies capable of neutralizing IL-4 and IL-13. Vaccination also significantly improved asthma symptoms.

The treatment reduced the level of IgE, eosonophylline, the development of mucus, as well as the hypersensitivity of the respiratory tract to the dust mites, showed observations.

Currently, the team is preparing for clinical trials.

According to statistics, about 350 million people in the world suffer from asthma and in 20% of them the disease is poorly controlled by existing drugs.

Previously scientists from the USA

We tell about the most interesting news and technologies — from the upcoming total automation to alternative energy, from artificial intelligence to the future medicine.

Hayk +